Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

10374	Companies
216189	Keywords
145888	Articles
114464	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 04/01/2025 at 22:15, 1 year 1 month ago

Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules
Jaguar Health, Inc. announces the closing of a private placement, issuing convertible promissory notes and unregistered warrants to selected investors, with gross proceeds of approximately $3.448 million

Private Placement Warrants Fundraising Jaguar Health Convertible Notes
BRIEF

published on 03/31/2025 at 14:05, 1 year 1 month ago

Jaguar Health affiche une croissance de son chiffre d'affaires de 20 % en 2024

Résultats Financiers Jaguar Health Produits Sur Ordonnance Réunion De La FDA Croissance Du Chiffre D'affaires En 2024
BRIEF

published on 03/31/2025 at 14:05, 1 year 1 month ago

Jaguar Health Shows 20% Revenue Growth in 2024

Financial Results Jaguar Health Prescription Products FDA Meeting 2024 Revenue Growth
PRESS RELEASE

published on 03/31/2025 at 14:00, 1 year 1 month ago

Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023
Jaguar Health, Inc. reports a 20% increase in total net revenue for 2024, reaching $11.7 million. Expecting first results in Q2 2025 for crofelemer trials. FDA meeting scheduled for Phase 3 OnTarget trial

Financial Results Jaguar Health Net Revenue FDA Meeting POC Trials
BRIEF

published on 03/28/2025 at 14:05, 1 year 1 month ago

Jaguar Health souligne son soutien vétérinaire à Canalevia-CA1

Canalevia-CA1 Approbation De La FDA Oncologie Vétérinaire Chimiothérapie Canine Traitement Non Antimicrobien
BRIEF

published on 03/28/2025 at 14:05, 1 year 1 month ago

Jaguar Health Highlights Veterinary Support for Canalevia-CA1

FDA Approval Canalevia-CA1 Veterinary Oncology Dog Chemotherapy Non-Antimicrobial Treatment
PRESS RELEASE

published on 03/28/2025 at 14:00, 1 year 1 month ago

83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey
Jaguar Health's Canalevia-CA1 receives FDA approval for chemotherapy-induced diarrhea in dogs, addressing a critical unmet need in veterinary oncology

FDA Approval Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea Veterinary Oncology
BRIEF

published on 03/27/2025 at 13:35, 1 year 1 month ago

Jaguar Health obtient une réunion avec la FDA pour discuter des résultats de l'essai Crofelemer sur le cancer du sein

Crofelemer Jaguar Health Cancer Du Sein Réunion De La FDA Étude OnTarget
BRIEF

published on 03/27/2025 at 13:35, 1 year 1 month ago

Jaguar Health Secures FDA Meeting to Discuss Crofelemer Results in Breast Cancer Trial

Crofelemer Jaguar Health Breast Cancer FDA Meeting OnTarget Study
PRESS RELEASE

published on 03/27/2025 at 13:30, 1 year 1 month ago

Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
Napo Pharmaceuticals presents statistically significant responder analysis results for crofelemer in breast cancer patients at San Antonio Breast Cancer Symposium and MASCC, FDA Type C Meeting scheduled for 2025

Napo Pharmaceuticals Crofelemer Breast Cancer FDA Meeting Responder Analysis

Accesswire

Published on 05/09/2026 at 01:55, 2 days 1 hour ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 2 days 1 hour ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 2 days 1 hour ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 2 days 3 hours ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 2 days 4 hours ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 05/10/2026 at 16:05, 11 hours 14 minutes ago

RingConn Gen 3 Smart Ring Opens for Pre-Order: Bringing Vascular Insights to Effortless Everyday Wear
Published on 05/10/2026 at 14:00, 13 hours 19 minutes ago

MBC GROUP DELIVERS RESILIENT 1Q 2026 PERFORMANCE ANCHORED BY STRONG MBC SHAHID GROWTH
Published on 05/10/2026 at 11:45, 15 hours 34 minutes ago

Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Published on 05/09/2026 at 19:05, 1 day 8 hours ago

LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 2 days 6 hours ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations

Les Echos

Published on 05/07/2026 at 19:15, 3 days 8 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 3 days 8 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 3 days 8 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 3 days 8 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 3 days 8 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE